Asparkam-Farmak - instructions for use, dose, side effects, contraindications

1 ml of the solution contains magnesium asparaginate anhydrous - 40 mg (3.37 mg magnesium), potassium asparaginate anhydrous - 45.2 mg (10.33 mg potassium), obtained by recipe: aspartic acid - 72.05 mg, magnesium oxide heavy in recalculation for 100% of the substance - 5.59 mg, potassium hydroxide in terms of 100% substance -14.82 mg;

Excipients: sorbitol - 50 mg, water for injection up to 1 ml.

Description:Transparent colorless or slightly yellowish liquid.

Pharmacotherapeutic group:Potassium and magnesium preparation

ATX: & nbsp

A.12.C.X Preparations of other minerals

Pharmacodynamics:Asparka-Farmak eliminates electrolyte imbalance in the body, facilitating the penetration of potassium and magnesium ions into the intracellular space. The drug has moderate antiarrhythmic properties, reducing the excitability of the myocardium, somewhat inhibits the conductance of the myocardium; reduces the increased sensitivity to cardiac glycosides and reduces the manifestation of their toxicity.

Pharmacokinetics:

Absorption is high. It is excreted by the kidneys.

Indications:

To eliminate the deficit (absolute or relative) of potassium and magnesium in various manifestations of coronary heart disease, including acute myocardial infarction; chronic circulatory failure; heart rhythm disorders caused by the use of cardiac glycosides; massive diuretic therapy, vomiting, diarrhea, etc.

Contraindications:

Hypersensitivity to the drug (including sorbitol and fructose), acute and chronic renal failure, hyperkalemia, atrioventricular blockade of I-III st., Severe myasthenia gravis, acute metabolic acidosis, hypermagnesia, metabolic disorders, arterial hypotension, dehydration (exsicosis) , hemolysis, Addison's disease, fructose-1,6-diphosphatase deficiency, methanol poisoning.

Carefully:

- In pregnancy (especially the first trimester) and during lactation;

- cardiogenic shock (systolic blood pressure less than 90 mm Hg), hypophosphatemia, severe hepatic insufficiency, metabolic acidosis, the risk of edema, CRF (in the event that regular monitoring of the concentration Mg2+ in the serum is impossible - the risk of cumulation).

Pregnancy and lactation:

Use with caution in pregnancy (especially the first trimester) and during lactation.

Dosing and Administration:

Enter intravenously drip or with a dosing device "Infusomat" or intravenously struino (slowly).

Intravenous appoint 10-20 ml once or twice a day for 5 days. Before use, the contents of 1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml are diluted in 100-200 ml of a 5% solution of dextrose (glucose) or a sterile 0.9% solution of sodium chloride and injected at a drop rate of 20-25 drops in minute, or dilute the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml in 20 ml of a 5% solution of dextrose (glucose) or a sterile 0.9% solution of sodium chloride and injected into the vein struino at a rate of not more than 5 ml per minute.

Side effects:

Nausea, vomiting, diarrhea, dry mouth, discomfort or burning sensation in the epigastric region (in patients with an anatomic gastritis or cholecystitis), abdominal pain, ulceration of the gastrointestinal mucosa, bleeding from the gastrointestinal tract, flatulence, dry mouth ; bradycardia, atrioventricular blockade, lowering of arterial pressure, paradoxical reaction (increase in the number of extrasystoles), dyspnoea, pruritus, hyperkalemia (nausea, vomiting, diarrhea, paresthesia),hypermagnia (redness of face, thirst, lowering blood pressure, hyporeflexia, respiratory depression, convulsions).

When injected, occasionally nausea and dizziness may occur, which usually occur with a decrease in the dose of the drug. Possible development of phlebitis, thrombosis. With rapid intravenous injection - hyperkalemia, hypermagnesia.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

With rapid jet injection or when the drug is administered at doses that significantly exceed therapeutic, hyperkalemia develops (muscular hypotension, paresthesia of limbs, slowing of atrioventricular conduction, arrhythmias, cardiac arrest), hypermagnesemia, which is manifested by reddening of the face, thirst, marked decrease in blood pressure, violation neuromuscular transmission, oppression of the respiratory center, arrhythmia, convulsions.

Treatment: Introduce calcium gluconate or calcium chloride 10% 10-40 ml (depending on the severity of the overdose), carry out activities to maintain respiratory function,hemodynamics. Symptomatic therapy. It is possible to conduct hemodialysis or peritoneal dialysis.

Interaction:

When used simultaneously with potassium-sparing diuretics, ACE inhibitors, beta-blockers, cyclosporine, heparin, non-steroidal anti-inflammatory drugs, the risk of hyperkalemia increases (serum potassium levels need to be monitored).

Asparka-Farmak reduces sensitivity to cardiac glycosides.

Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs.

Eliminates hypokalemia caused by glucocorticosteroids and diuretics. General anesthetics increase the inhibitory effect on the central nervous system; when used simultaneously with atrakuronium, decamethonium, succinyl chloride and suxamethonium, neuromuscular blockade may be strengthened.

Special instructions:

Attention! With rapid intravenous administration, hyperkalemia and hypermagnesemia can develop, with the occurrence of arrhythmias threatening the patient's life, therefore a rapid intravenous injection of the drug is contraindicated!

If necessary, the use of the drug during pregnancy and during the period lactation.

If necessary, treatment with Asparkam-Farmak can be combined with the use of strophanthin and cardiac glycosides. If necessary, solutions of cardiac glycosides can be added to the solution of the drug.

Injection solution is used in inpatient and outpatient settings.

Effect on the ability to drive transp. cf. and fur:During drug treatment it is necessary to refrain from driving or working with complex mechanisms.

Form release / dosage:Solution for intravenous administration.

Packaging:

5 ml, 10 ml or 20 ml into glass ampoules with a kink ring or break point.

For 10 ampoules, together with instructions for medical use, are placed in a pack of cardboard with corrugated tabs.

Or 5 ampoules are put in a blister of polymer film. Two blisters with ampoules, along with instructions for medical use, are put in a pack of cardboard.

Storage conditions:

In the dark place at a temperature of 15 ° C to 25 ° C. Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N015825 / 01

Date of registration:12.02.2010 / 27.04.2016

Expiration Date:Unlimited

The owner of the registration certificate:FARMAK, PAO FARMAK, PAO Ukraine

Manufacturer: & nbsp

FARMAK, PAO Ukraine

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

Asparks-Farmak (Asparcam-Farmak)